BCO entered its Q1 2026 earnings release today with one of the sharpest short-selling buildups seen in the past two months — and despite a genuine beat on both revenue and profit, the question now is whether that conviction unwinds or digs in.
The short interest story is the defining tension this week. Estimated short interest has nearly doubled since late March, climbing from roughly 3% of the free float on March 25 to 5.85% by May 5 — an 88% increase over 30 days. The acceleration picked up meaningfully through April: shorts stood at 4.2% at the start of the month, crossed 4.7% in mid-April, and pushed above 5.5% in the final week before the print. That trajectory — steady, deliberate accumulation rather than a single jump — points to a thesis being built, not a reactive hedge. The ORTEX short score climbed from 40.5 to 45.6 over the past two weeks, confirming the direction of travel.
The lending market tells a more nuanced story. Availability is not tight. Cost to borrow runs at just 0.39%, and the borrow has barely moved over the month. New shorts are getting in cheaply and without friction. That means the pressure being applied is not a squeeze setup — it's low-cost conviction from sellers who see fundamental reasons to be short ahead of and through the earnings event. Borrow availability remains ample relative to the short position, so there is no mechanical catalyst forcing a rapid unwind.
What the bears were betting against materialised only partially. Q1 adjusted EPS came in at $1.80 against a $1.56 estimate — a meaningful beat. Revenue of $1.375 billion topped the $1.346 billion forecast. Brink's itself called it "strong first-quarter results with double-digit revenue growth." Q2 guidance, however, offered shorts a foothold: the company guided adjusted EPS to a range of $1.85–$2.25, with the midpoint sitting broadly in line with the $2.09 consensus. Sales guidance of $1.37–$1.43 billion also straddles rather than clearly clears the $1.389 billion estimate. In February, the stock dropped nearly 10% the day after the prior quarter's results — a print where expectations were clearly not met. This time, the beat is real, but the guide leaves room for debate.
The analyst community had been broadly supportive heading in. Goldman Sachs raised its target to $145 in early March, maintaining a Buy. Truist Securities lifted its target to $163 in February, also keeping a Buy. Both of those moves are now more than two months old and predate today's print — the mean target of $154 sits nearly 48% above the $104.30 close, a gap that reflects either genuine undervaluation or targets that have not yet caught up with a stock that peaked above $125 in early March before sliding. The institutional base is stable: BlackRock, Fidelity, and Vanguard collectively hold more than 33% of shares. First Trust Advisors added 218,716 shares in the most recent reporting period — the largest single addition among major holders. That steady institutional footprint provides a floor, but it doesn't resolve the near-term debate the shorts are pressing.
One notable backdrop: a news item from May 5 flagged shareholder pushback over transparency related to a merger, which adds a layer of corporate noise that could extend the uncertainty period beyond the earnings event. The CEO and CFO both sold shares in early March at $125.83 — roughly 17% above the current price — a reminder that insiders were lightening up near the peak, even as the institutional base has held broadly steady since.
What to watch now is whether the Q2 guidance midpoint is enough to arrest the short buildup — or whether sellers treat an in-line forward guide as license to press further into a stock trading nearly 50 dollars below the mean analyst target.
See the live data behind this article on ORTEX.
Open BCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
